Literature DB >> 23173980

Molecular genetic analysis of 16 XP-C patients from Germany: environmental factors predominately contribute to phenotype variations.

Annika Schäfer1, Lars Hofmann, Alexei Gratchev, Petra Laspe, Steffen Schubert, Anke Schürer, Andreas Ohlenbusch, Mladen Tzvetkov, Christian Hallermann, Jörg Reichrath, Michael P Schön, Steffen Emmert.   

Abstract

Patients belonging to xeroderma pigmentosum (XP) complementation group C comprise one-third of all XP patients. Only four major reports compiled larger groups of XP-C patients from southern Europe (12 pts), North America (16 pts) and Africa (14 and 56 pts) as well as their genetic background (46 XPC mutations). We identified 16 XP-C patients from Germany. Interestingly, only five patients exhibited severe sun sensitivity. The mean age of XP diagnosis was 9.4 years, and the median age of the first skin cancer was 7 years. Neurological symptoms were absent in all but two patients. Primary fibroblasts from all 16 patients showed reduced post-UV cell survival (mean: 50% vs 93% in normal cells) and reduced reactivation of an UV-treated luciferase reporter gene (mean: 6.4% vs 30.7% in normal cells). XPC mRNA expression was also greatly reduced compared with normal cells (mean: 14.3%; range 8.3-25.7%) except in XP47MA (274.1%). All patients carried homozygous XPC mutations. Four mutations have been described previously: c.1747_1748delTG (found in 4/16), c.567 C>T (4/16), c.1839 C>T (1/16) and a complex insertion/deletion mutation in exon 9 (1/16). The novel frameshift mutations c.446_447delAG (2/16), c.1525insA (1/16) and c.2271delC (1/16) lead to truncated XPC proteins as does the novel nonsense mutation c.843C>T (1/16). XP47MA carries an interesting mutation (c.2538_2540delATC; p.Ile812del) resulting in an in-frame single amino acid deletion. This mutation results in a classical XP phenotype, a non-functional XPC protein, but elevated XPC mRNA expression. Our study indicates that extrinsic factors may contribute to XP-C symptom severity due to nonsense-mediated message decay.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23173980     DOI: 10.1111/exd.12052

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  6 in total

Review 1.  Clinical utility gene card for: Xeroderma pigmentosum.

Authors:  Steffen Schubert; Janin Lehmann; Limor Kalfon; Hanoch Slor; Tzipora C Falik-Zaccai; Steffen Emmert
Journal:  Eur J Hum Genet       Date:  2013-10-09       Impact factor: 4.246

2.  XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF.

Authors:  Janin Lehmann; Christina Seebode; Sabine Smolorz; Steffen Schubert; Steffen Emmert
Journal:  Cell Mol Life Sci       Date:  2017-01-27       Impact factor: 9.261

3.  Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons.

Authors:  Christiane Kuschal; John J DiGiovanna; Sikandar G Khan; Richard A Gatti; Kenneth H Kraemer
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

4.  Identification of a novel protein truncating mutation p.Asp98* in XPC associated with xeroderma pigmentosum in a consanguineous Pakistani family.

Authors:  Muhammad Z Ali; Jasmin Blatterer; Muzammil A Khan; Erich Schaflinger; Erwin Petek; Safeer Ahmad; Ejazullah Khan; Christian Windpassinger
Journal:  Mol Genet Genomic Med       Date:  2020-01-10       Impact factor: 2.183

5.  Clinical and Mutational Spectrum of Xeroderma Pigmentosum in Egypt: Identification of Six Novel Mutations and Implications for Ancestral Origins.

Authors:  Eman Rabie; Khalda Amr; Suher Zada; Heba El-Sayed; Mohamad El Darouti; Ghada El-Kamah
Journal:  Genes (Basel)       Date:  2021-02-20       Impact factor: 4.096

6.  Whole-exome sequencing enables rapid determination of xeroderma pigmentosum molecular etiology.

Authors:  Oscar Ortega-Recalde; Jéssica Inés Vergara; Dora Janeth Fonseca; Xiomara Ríos; Hernando Mosquera; Olga María Bermúdez; Claudia Liliana Medina; Clara Inés Vargas; Argemiro Enrique Pallares; Carlos Martín Restrepo; Paul Laissue
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.